Tracking babies born to migraine moms on aimovig
NCT ID NCT06150781
Summary
This study aims to understand the safety of the migraine medication Aimovig (erenumab) during pregnancy. It will follow pregnant women with migraines who are either taking Aimovig or not, to compare rates of major birth defects and other pregnancy outcomes in their babies. The goal is to gather safety information to help future patients and doctors make informed decisions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IQVIA Virtual Site
RECRUITINGDurham, North Carolina, 27703, United States
Conditions
Explore the condition pages connected to this study.